

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Weibel et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: October 31, 2003

Examiner: To be assigned

For: New Pharmaceutical Composition And The Process for its Preparation

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of all references were either submitted to, or cited by, the Patent Office in parent application USSN 09/863,986 filed on May 23, 2001.

The references are as follows:

1. US 5,480,652


2. WO 95/06461
3. WO 96/18386
4. WO 96/34606
5. WO 97/41097
6. WO 00/32191
7. EPO 945 134 A1
8. Biosis An 1989:475692, Aly et al., Acta Pharm Fenn, 1989, 98(1), 21-32, abstract

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: October 31, 2003

Respectfully submitted,



Reza Green, Reg. No. 38,475
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449 (Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Atty. Docket No. 6206.210-US	Serial No. To be assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant Weibel et al.	
(Use several sheets if necessary)		Filing Date October 31, 2003	Group To be assigned

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 97/41097	11/06/9	PCT				
		WO 96/18386	06/20/96	PCT				
		WO 96/34606	11/07/96	PCT				
		WO 00/32191	06/08/2000	PCT				
		WO 95/06461	03/09/95	PCT				
		EP 0 945 134 A1	09/29/99	EPO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Biosis An 1989:475692 Alv et al., Acta Pharm Fenn. 1989, 98(1), 21-32, abstract

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.